The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours
Publication in refereed journal
Full Text
View Full-text in CUHK Digital Object Identifier (DOI) DOI for CUHK Users View Full-text in Publisher Website  |
Times Cited
Altmetrics Information
.
Other information
AbstractBackground The integration of next-generation sequencing (NGS) comprehensive gene profiling (CGP) into clinical
practice is playing an increasingly important role in oncology. Therefore, the HKU-HKSH Multi-disciplinary
Molecular Tumour Board (MTB) was established to advance precision oncology in Hong Kong. A multicenter
retrospective study investigated the feasibility of the HKU-HKSH MTB in determining genome-guided therapy for
treatment-refractory solid cancers in Hong Kong.
Methods Patients who were presented at the HKU-HKSH MTB between August 2018 and June 2022 were included in
this study. The primary study endpoints were the proportion of patients who receive MTB-guided therapy based on
genomic analysis and overall survival (OS). Secondary endpoints included the proportion of patients with actionable
genomic alterations, objective response rate (ORR), and disease control rate (DCR). The Kaplan–Meier method was
used in the survival analyses, and hazard ratios were calculated using univariate Cox regression.
Findings 122 patients were reviewed at the HKU-HKSH MTB, and 63% (n = 77) adopted treatment per the MTB
recommendations. These patients achieved a significantly longer median OS than those who did not receive MTBguided therapy (12.7 months vs. 5.2 months, P = 0.0073). Their ORR and DCR were 29% and 65%, respectively.
Interpretation Our study demonstrated that among patients with heavily pre-treated advanced solid cancers, MTBguided treatment could positively impact survival outcomes, thus illustrating the applicability of NGS CGPs in
real-world clinical practice.
Funding The study was supported by the Li Shu Pui Medical Foundation. Dr Aya El Helali was supported by the Li
Shu Pui Medical Foundation Fellowship grant from the Li Shu Pui Medical Foundation. Funders had no role in study
design, data collection, data analysis, interpretation, or writing of the report.
practice is playing an increasingly important role in oncology. Therefore, the HKU-HKSH Multi-disciplinary
Molecular Tumour Board (MTB) was established to advance precision oncology in Hong Kong. A multicenter
retrospective study investigated the feasibility of the HKU-HKSH MTB in determining genome-guided therapy for
treatment-refractory solid cancers in Hong Kong.
Methods Patients who were presented at the HKU-HKSH MTB between August 2018 and June 2022 were included in
this study. The primary study endpoints were the proportion of patients who receive MTB-guided therapy based on
genomic analysis and overall survival (OS). Secondary endpoints included the proportion of patients with actionable
genomic alterations, objective response rate (ORR), and disease control rate (DCR). The Kaplan–Meier method was
used in the survival analyses, and hazard ratios were calculated using univariate Cox regression.
Findings 122 patients were reviewed at the HKU-HKSH MTB, and 63% (n = 77) adopted treatment per the MTB
recommendations. These patients achieved a significantly longer median OS than those who did not receive MTBguided therapy (12.7 months vs. 5.2 months, P = 0.0073). Their ORR and DCR were 29% and 65%, respectively.
Interpretation Our study demonstrated that among patients with heavily pre-treated advanced solid cancers, MTBguided treatment could positively impact survival outcomes, thus illustrating the applicability of NGS CGPs in
real-world clinical practice.
Funding The study was supported by the Li Shu Pui Medical Foundation. Dr Aya El Helali was supported by the Li
Shu Pui Medical Foundation Fellowship grant from the Li Shu Pui Medical Foundation. Funders had no role in study
design, data collection, data analysis, interpretation, or writing of the report.
All Author(s) ListEl Helali A., Lam T.C., Ko E.Y.L., Shih D.J.H., Chan C.K., Wong C.H.L., Wong J.W.H., Cheung L.W.T., Lau J.K.S., Liu A.P.Y., Chan A.S.Y., Loong H.H., Lam S.T.S., Chan G.C.F., Lee V.H.F., Yuen K.K., Ng W.T., Lee A.W.M., Ma E.S.K.
Journal nameThe Lancet Regional Health - Western Pacific
Year2023
Month7
Volume Number36
PublisherElsevier
Article number100775
eISSN2666-6065
LanguagesEnglish-United Kingdom
KeywordsMolecular tumour board, Next-generation sequencing, Precision oncology, Sequence-directed therapy
